Biocon's contract research arm Syngene International has expanded its ongoing drug discovery and development with US-based Bristol-Myers Squibb till 2026. The company today said the expanded scope of partnership also includes addition of a new facility and ramping up the team of scientists working for it. "The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations, an expansion of the team and the extension of the existing agreement through 2026," Syngene International said in a BSE filing. "The expansion will enable the two companies to undertake a greater range of scientific research and development for pharmaceuticals across a broader range of activities," it added. As part of the expansion, Syngene will set up a new dedicated facility spread across 25,000 sq ft of laboratory and office space for Bristol-Myers Squibb. This facility will house an additional team of 75 Syngene scientists who will work exclusively for Bristol-Myers Squibb. Syngene and Bristol-Myers Squibb have been working together since 1998.
The research campus, known as Biocon BMS Research Center (BBRC), Syngene's first dedicated R&D centre, was established in 2007, which was subsequently renewed through 2020 and now has been extended through 2026. It is the largest research and development facility for Bristol-Myers Squibb outside the United States and plays an integral part within their global research and development network, Syngene said.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)